Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 9/2011

01-09-2011 | Review

Lung cancer and Toll-like receptors

Authors: Aldo Pinto, Silvana Morello, Rosalinda Sorrentino

Published in: Cancer Immunology, Immunotherapy | Issue 9/2011

Login to get access

Abstract

Lung carcinoma is one of the leading causes of death worldwide. It is a non-immunogenic cancer, resistant to immune surveillance. Toll-like receptors (TLRs) connect the innate to the adaptive immune system. Given that cancerous cells evade the immune system, the activation of TLRs could represent a potential target for cancer therapy. The induction of Th1-like and cytotoxic immunity by TLR signalling could lead to tumour cell death, resulting in tumour regression or arrest. However, basic research and clinical trials revealed that the activation of specific TLRs, such as TLR2, TLR4 and TLR9, do not have any anti-tumour activity in lung carcinoma. Increasing evidence suggests that TLRs are important regulators of tumour biology; however, little is known about their function in lung cancer. Thus, in order to develop new therapeutic approaches, further studies are needed to understand the connection between TLRs and lung cancer progression. This review focuses on the potential mechanisms by which TLR ligands can facilitate or not lung cancer and lung metastases establishment/progression.
Literature
1.
Jahrsdorfer B, Weiner GJ (2008) CpG oligodeoxynucleotides as immunotherapy in cancer. Cancer Ther 3(1):27–32
2.
Igney FH, Krammer PH (2002) Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leuk Biol 71(6):07–20
3.
Prendergast GC (2008) Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 27(28):3889–3900PubMedCrossRef
4.
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30(7):1073–1081PubMedCrossRef
5.
Wang RF, Peng G, Wang HY (2006) Regulatory T cells and toll-like receptors in tumor immunity. Semin Immunol 18:136–142PubMedCrossRef
6.
Mitchell JA, Paul-Clark MJ, Clarke GW, McMaster SK, Cartwright N (2007) Critical role of toll-like receptors and nucleotide oligomerisation domain in the regulation of health and disease. J Endocrinol 193(3):323–330PubMedCrossRef
7.
Kluwe J, Mencin A, Schwabe RF (2009) Toll like receptors, Wound healing and carcinogenesis. J mol Med 87(2):125–138PubMedCrossRef
8.
9.
Sorrentino R, de Souza PM, Sriskandan S, Duffin C, Paul-Clark MJ, Mitchell JA (2008) Pattern recognition receptors and interleukin-8 mediate effects of Gram-positive and Gram-negative bacteria on lung epithelial cell function. Br J Pharmacol 154(4):864–871PubMedCrossRef
10.
Iwamura C, Nakayama T (2008) Toll-like receptors in the respiratory system: their roles in inflammation. Curr Allergy Asthma Rep 8(1):7–13PubMedCrossRef
11.
Yu L, Chen S (2008) Toll-like receptors expressed in tumour cells: targets for therapy. Cancer Immunol Immunther 57:1271–1278CrossRef
12.
Cherfils-Vicini J, Platonova S, Gillard M, Laurans L, Validire P, Caliandro R, Magdeleinat P, Mami-Chouaib F, Dieu-Nosjean MC, Fridman WH, Damotte D, Sautès-Fridman C, Cremer I (2010) Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 120(4):1285–1297PubMedCrossRef
13.
Koff JL, Shao MX, Ueki IF, Nadel JA (2008) Multiple TLRs activate EGFR via a signalling cascade to produce innate immune responses in airway epithelium. Am J Physiol Lung Cell Mol Physiol 294:L1068–L1075PubMedCrossRef
14.
Lechmann M, Zinser E, Golka A, Steinkasserer A (2002) Role of CD83 in the immunomodulation of dendritic cells. Int Arch Allergy Immunol 129(2):113–118PubMedCrossRef
15.
Doganci A, Eigenbrod T, Krug N, De Sanctis GT, Hausding M, Erpenbeck VJ, Haddad El-B, Lehr HA, Schmitt E, Bopp T, Kallen KJ, Herz U, Schmitt S, Luft C, Hecht O, Hohlfeld JM, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Rose-John S, Renz H, Neurath MF, Galle PR, Finotto S (2005) The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest 115(2):313–325PubMed
16.
Reiner S, Sallusto F, Lanzavecchia A (2007) Division of labor with a workforce of one: challenges in specifying effector and memory T cell fate. Science 317:622–625PubMedCrossRef
17.
Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206(7):1457–1464PubMedCrossRef
18.
Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31(5):787–798PubMedCrossRef
19.
Shepard HM, Brdlik CM, Schreiber H (2008) Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest 118(11):3574–3581PubMedCrossRef
20.
Eisenbarth SC, Piggott DA, Bottomly K (2003) The master regulators of allergic inflammation: dendritic cells in Th2 sensitization. Curr Opin Immunol 15(6):620–626PubMedCrossRef
21.
Piggott DA, Eisenbarth SC, Xu L, Constant SL, Huleatt JW, Herrick CA, Bottomly K (2005) MyD88-dependent induction of allergic Th2 responses to intranasal antigen. J Clin Invest 115(2):459–467PubMed
22.
Sorrentino R, Morello S, Luciano A, Crother TR, Maiolino P, Bonavita E, Arra C, Adcock IM, Arditi M, Pinto A (2010) Plasmacytoid dendritic cells alter the antitumor activity of CpG-oligodeoxynucleotides in a mouse model of lung carcinoma. J Immunol 185(8):4641–4650PubMedCrossRef
23.
Lambrecht BN, Hammad H (2010) The role of dendritic and epithelial cells as master regulators of allergic airway inflammation. Lancet 376(9743):835–843PubMedCrossRef
24.
Sorrentino R, Morello S, Pinto A (2010) Role of plasmacytoid dendritic cells in lung-associated inflammation. Recent Pat Inflamm Allergy Drug Discov 4(2):138–143PubMedCrossRef
25.
26.
Jankowska O, Krawczyk P, Wojas-Krawczyk K, Sagan D, Milanowski J, Roliński J (2008) Phenotype of dendritic cells generated in the presence of non-small cell lung cancer antigens—preliminary report. Folia Histochem Cytobiol 46(4):465–470PubMedCrossRef
27.
Sorrentino R, Gray P, Chen S, Shimada K, Crother TR, Arditi M (2010) Plasmacytoid dendritic cells prevent cigarette smoke and Chlamydophila pneumoniae-induced Th2 inflammatory responses. Am J Respir Cell Mol Biol 43(4):422–431PubMedCrossRef
28.
Xu H, Zhang GX, Ciric B, Rostami A (2008) IDO: a double-edged sword for T(H)1/T(H)2 regulation. Immunol Lett 121(1):1–6PubMedCrossRef
29.
de Heer HJ, Hammad H, Soullié T, Hijdra D, Vos N, Willart MA, Hoogsteden HC, Lambrecht BN (2004) Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med 200(1):89–98PubMedCrossRef
30.
Smit JJ, Lindell DM, Boon L, Kool M, Lambrecht BN, Lukacs NW (2008) The balance between plasmacytoid DC versus conventional DC determines pulmonary immunity to virus infections. PLoS One 3(3):e1720PubMedCrossRef
31.
Akira S, Sato S (2003) Toll-like receptors and their signaling mechanisms. Scand J Infect Dis 35(9):555–562PubMedCrossRef
32.
Smyth MJ (2005) Type I interferon and cancer immunoediting. Nature Immunol 6:646–648CrossRef
33.
Fabricius D, Neubauer M, Mandel B, Schütz C, Viardot A, Vollmer A, Jahrsdörfer B, Debatin KM (2010) Prostaglandin E2 inhibits IFN-alpha secretion and Th1 costimulation by human plasmacytoid dendritic cells via E-prostanoid 2 and E-prostanoid 4 receptor engagement. J Immunol 184(2):677–684PubMedCrossRef
34.
Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH (2007) Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2, 3-dioxygenase. J Clin Invest 117(9):2570–2582PubMedCrossRef
35.
Tokita D, Mazariegos GV, Zahorchak AF, Chien N, Abe M, Raimondi G, Thomson AW (2008) High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. Transplantation 85(3):369–377PubMedCrossRef
36.
Karanikas V, Zamanakou M, Kerenidi T, Dahabreh J, Hevas A, Nakou M, Gourgoulianis KI, Germenis AE (2007) Indoleamine 2, 3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther 6(8):1258–1262PubMedCrossRef
37.
Gregori S, Bacchetta R, Passerini L, Levings MK, Roncarolo MG (2007) Isolation, expansion, and characterization of human natural and adaptive regulatory T cells. Methods Mol Biol 380:83–105PubMedCrossRef
38.
Lee YK, Mukasa R, Hatton RD, Weaver CT (2009) Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol 21(3):274–280PubMedCrossRef
39.
Gerondakis S, Grumont RJ, Banerjee A (2007) Regulating B-cell activation and survival in response to TLR signals. Immunol Cell Biol 85:471–475PubMedCrossRef
40.
Sorrentino R, Morello S, Forte G, Montinaro A, De Vita G, Luciano A, Palma G, Arra C, Maiolino P, Adcock IM, Pinto A. (2011) B Cells contribute to the anti-tumour activity of CpG-ODN in a mouse model of metastatic lung carcinoma. Am J Respir Crit Care Med
41.
Inoue S, Leitner WW, Golding B, Scott D (2006) Inhibitory effects of B cells on antitumour immunity. Cancer Res 66:7741–7747PubMedCrossRef
42.
Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22(2):231–237PubMedCrossRef
43.
Glaros T, Larsen M, Li L (2009) Macrophages and fibroblasts during inflammation, tissue damage and organ injury. Front Biosci 14:3988–3993PubMedCrossRef
44.
Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M (2009) Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457(7225):102–106PubMedCrossRef
45.
Lee CH, Wu CL, Shiau AL (2010) Toll-like receptor 4 signaling promotes tumor growth. J Immunother 33(1):73–82PubMedCrossRef
46.
Nagaraj S, Collazo M, Corzo CA, Youn JI, Ortiz M, Quiceno D, Gabrilovich DI (2009) Regulatory myeloid suppressor cells in health and disease. Cancer Res 69(19):7503–7506PubMedCrossRef
47.
Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, Boireau W, Rouleau A, Simon B, Lanneau D, De Thonel A, Multhoff G, Hamman A, Martin F, Chauffert B, Solary E, Zitvogel L, Garrido C, Ryffel B, Borg C, Apetoh L, Rébé C, Ghiringhelli F (2010) Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 120(2):457–471PubMed
48.
Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nature 6:392–401
49.
Nahoum Rakoff, Medzhitov R (2008) Role of toll-like receptors in tissue repair and tumorigenesis. Biochemistry 73:555–561
50.
Luo JL, Maeda S, Hsu LC, Yagita H, Karin M (2004) Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6:297–305PubMedCrossRef
51.
Li X, Jiang S, Tapping RI (2010) Toll-like receptors signalling in cell proliferation and survival. Cytokine 49:1–9PubMedCrossRef
52.
Zitvogel L, Terme M, Borg C, Trinchieri G (2006) Dendritic cell-NK cell cross-talk: regulation and physiopathology. Curr Top Microbiol Immunol 298:157–174PubMedCrossRef
53.
Akazawa T, Masuda H, Saeki Y, Matsumoto M, Takeda K, Tsujimura K, Kuzushima K, Takahashi T, Azuma I, Akira S, Toyoshima K, Seya T (2004) Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice. Cancer Res 64(2):757–764PubMedCrossRef
54.
Akazawa T, Ebihara T, Okuno M, Okuda Y, Shingai M, Tsujimura K, Takahashi T, Ikawa M, Okabe M, Inoue N, Okamoto-Tanaka M, Ishizaki H, Miyoshi J, Matsumoto M, Seya T (2007) Antitumor NK activation induced by the toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci USA 104(1):252–257PubMedCrossRef
55.
Cheng YS, Xu F. (2010) Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol Ther. 10(12)
56.
Chin AI, Miyahira AK, Covarrubias A, Teague J, Guo B, Dempsey PW, Cheng G (2010) Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res 70(7):2595–2603PubMedCrossRef
57.
McCartney S, Vermi W, Gilfillan S, Cella M, Murphy TL, Schreiber RD, Murphy KM, Colonna M (2009) Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med 206(13):2967–2976PubMedCrossRef
58.
Lowe DB, Shearer MH, Aldrich JF, Winn RE, Jumper CA, Kennedy RC (2010) Role of the innate immune response and tumor immunity associated with simian virus 40 large tumor antigen. J Virol 84(19):10121–10130PubMedCrossRef
59.
Hirsch I, Caux C, Hasan U, Bendriss-Vermare N, Olive D (2010) Impaired toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. Trends Immunol 31(10):391–397PubMedCrossRef
60.
Sawahata R, Shime H, Yamazaki S, Inoue N, Akazawa T, Fujimoto Y, Fukase K, Matsumoto M, Seya T (2011) Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2. Microbes Infect 13(4):350–358PubMedCrossRef
61.
Ma F, Zhang J, Zhang J, Zhang C (2010) The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell Mol Immunol 7(5):381–388PubMedCrossRef
62.
Zanoni I, Foti M, Ricciardi-Castagnoli P, Granucci F (2005) TLR-dependent activation stimuli associated with Th1 responses confer NK cell stimulatory capacity to mouse dendritic cells. J Immunol 175(1):286–292PubMed
63.
Hamm S, Rath S, Michel S, Baumgartner R (2009) Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists. J Immunotoxicol 6(4):257–265PubMedCrossRef
64.
Groot Kormelink T, Abudukelimu A, Redegeld FA (2009) Mast cells as target in cancer therapy. Curr Pharm Des 15(16):1868–1878PubMedCrossRef
65.
Tomita M, Matsuzaki Y, Onitsuka T (2000) Effect of mast cells on tumour angiogenesis in lung cancer. Am Thorac Surg 69:1686–1690CrossRef
66.
Welsh TJ, Green RH, Richardson D, Waller A, O’Byrne KJ, Bradding P (2005) Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 23:8959–8967PubMedCrossRef
67.
Oldford SA, Haidl ID, Howatt MA, Leiva CA, Johnston B, Marshall JS (2010) A critical role for mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth. J Immunol 185(11):7067–7076PubMedCrossRef
68.
Tsai YG, Yang KD, Niu DM, Chien JW, Lin CY (2010) TLR2 agonists enhance CD8+Foxp3+ regulatory T cells and suppress Th2 immune responses during allergen immunotherapy. J Immunol 184(12):7229–7237PubMedCrossRef
69.
Matsushima H, Yamada N, Matsue H, Shimada S (2004) TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J Immunol 173(1):531–541PubMed
70.
Nigo YI, Yamashita M, Hirahara K, Shinnakasu R, Inami M, Kimura M, Hasegawa A, Kohno Y, Nakayama T (2006) Regulation of allergic airway inflammation through Toll-like receptor 4-mediated modification of mast cell function. Proc Natl Acad Sci USA 103(7):2286–2291PubMedCrossRef
71.
Ikeda RK, Miller M, Nayar J, Walker L, Cho JY, McElwain K, McElwain S, Raz E, Broide DH (2003) Accumulation of peribronchial mast cells in a mouse model of ovalbumin allergen induced chronic airway inflammation: modulation by immunostimulatory DNA sequences. J Immunol 171(9):4860–4867PubMed
72.
Kulka M, Metcalfe DD. (2006) TLR3 activation inhibits human mast cell attachment to fibronectin and vitronectin. Mol Immunol. 1579-1586
73.
Iwamura C, Nakayama T (2008) Toll-like receptors in the respiratory system: their roles in inflammation. Curr Allergy Asthma Rep 8(1):7–13PubMedCrossRef
74.
Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nature 6:392–401
75.
Damiano V, Caputo R, Garofalo S, Bianco R, Rosa R, Merola G, Gelardi T, Racioppi L, Fontanini G, De Placido S, Kandimalla ER, Agrawal S, Ciardiello F, Tortora G (2007) TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci USA 104(30):12468–12473PubMedCrossRef
76.
Droemann D, Albrecht D, Gerdes J, Ulmer AJ, Branscheid D, Vollmer E, Dalhoff K, Zabel P, Goldmann T (2005) Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res 6:1PubMedCrossRef
77.
Wenzel J, Uerlich M, Haller O, Bieber T, Tueting T (2005) Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod. J Cutan Pathol 32(4):257–262PubMedCrossRef
78.
Johnson B, Osada T, Clay T, Lyerly H, Morse M (2009) Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression. Curr Mol Med 9(6):702–707PubMedCrossRef
79.
Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306–1309PubMedCrossRef
80.
Sorrentino R, Morello S, Giordano MG, Arra C, Maiolino P, Adcock IM, Pinto A (2011) CpG-ODN increases the release of VEGF in a mouse model of lung carcinoma. Int J Cancer 128(12):2815–2822PubMedCrossRef
81.
Chapoval SP, Lee CG, Tang C, Keegan AD, Cohn L, Bottomly K, Elias JA (2009) Lung vascular endothelial growth factor expression induces local myeloid dendritic cell activation. Clin Immunol 132(3):371–384PubMedCrossRef
82.
Elenbaas B, Weinberg RA (2001) Heterotypic signalling between epithelial tumour cells and fibroblasts in carcinoma formation. Exp Cell Res 264(1):169–184PubMedCrossRef
83.
Li J, Ma Z, Tang ZL, Stevens T, Pitt B, Li S (2004) CpG DNA-mediated immune response in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 287(3):L552–L558PubMedCrossRef
84.
Bedke T, Pretsch L, Karakhanova S, Enk AH, Mahnke K (2010) Endothelial cells augment the suppressive function of CD4+ CD25+ Foxp3+ regulatory T cells: involvement of programmed death-1 and IL-10. J Immunol 184(10):5562–5570PubMedCrossRef
85.
Engelhardt R, Otto F, Mackensen A, Mertelsmann R, Galanos C (1995) Endotoxin (Salmonella abortus equi) in cancer patients Clinical and immunological findings. Prog Clin Biol Res 392:253–261PubMed
86.
Liu C, Lou Y, Lizée G, Qin H, Liu S, Rabinovich B, Kim GJ, Wang YH, Ye Y, Sikora AG, Overwijk WW, Liu YJ, Wang G, Hwu P (2008) Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 118(3):1165–1175PubMed
87.
Luo JL, Maeda S, Hsu LC, Yagita H, Karin M (2004) Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6:297–305PubMedCrossRef
88.
Li X, Jiang S, Tapping RI (2010) Toll-like receptors signalling in cell proliferation and survival. Cytokine 49:1–9PubMedCrossRef
Metadata
Title
Lung cancer and Toll-like receptors
Authors
Aldo Pinto
Silvana Morello
Rosalinda Sorrentino
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 9/2011
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-011-1057-8

Other articles of this Issue 9/2011

Cancer Immunology, Immunotherapy 9/2011 Go to the issue

Original Article

Skin tumor responsiveness to interleukin-2 treatment and CD8 Foxp3+ T cell expansion in an immunocompetent mouse model

Opinion Paper

Therapeutic effects of metformin in breast cancer: involvement of the immune system?

Short communication

Obituary: Joseph Lustgarten, 1963–2011

Original article

Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4+ and CD8+ T cells

Original article

CTL recognition of a novel HLA-A*0201-binding peptide derived from glioblastoma multiforme tumor cells

Original article

Immunotherapy eradicates metastases with reversible defects in MHC class I expression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits